Adherence to Clinical Trial Supported Evaluation of Optic Neuritis

References

• Volpe NJ. The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol. 2008;126:996–999. doi:10.1001/archopht.126.7.996.
   PubMedGoogle Scholar
• Beck RW, Cleary PA, Jye-Yu C. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology. 1994;101:1771–1778.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Jr MM A, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. New Engl J Med. 1992;326(9):581–588. doi:10.1056/NEJM199202273260901.
   PubMed Web of Science ®Google Scholar
• Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10(8):447. doi:10.1038/nrneurol.2014.108.
   PubMed Web of Science ®Google Scholar
• Beck RW. The optic neuritis treatment trial: implications for clinical practice. Arch Ophthalmol. 1992;110:331–332.
   PubMed Web of Science ®Google Scholar
• Jd T, Pc S, Ke G, Fendrick AM. The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists. Ophthalmology. 1992;106:2047–2053.
   Google Scholar
• Biousse V, Calvetti O, Drews-Botsch CD, et al. Management of optic neuritis and impact of clinical trials: an international survey. J Neurol Sci. 2009;276(1):69–74. doi:10.1016/j.jns.2008.08.039.
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and post-injection endophthalmitis rates. Ophthalmology. 2015;122(11):2311–2315. doi:10.1016/j.ophtha.2015.07.005.
   PubMed Web of Science ®Google Scholar
• VanderBeek BL, Shah N, Parikh PC, Ma L. Trends in the care of diabetic macular edema: analysis of a national cohort. PLoS One. 2016;11(2):e0149450. doi:10.1371/journal.pone.0149450.
   PubMed Web of Science ®Google Scholar
• Vanderbeek BL, Zacks DN, Talwar N, et al. Racial differences in age-related macular degeneration rates in the United States: a longitudinal analysis of a managed care network. Am J Ophthalmol. 2011;152(2):273–282. doi:10.1016/j.ajo.2011.02.004.
   PubMed Web of Science ®Google Scholar
• Cestari DM, Gaier ED, Bouzika P, et al. Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 2016;123(12):2446–2455. doi:10.1016/j.ophtha.2016.08.017.
   PubMed Web of Science ®Google Scholar
• Sarezky D, Orlin SE, Pan W, VanderBeek BL. Trends in Corneal Transplantation in Keratoconus. Cornea. 2017;36(2):131–137. doi:10.1097/ICO.0000000000001083.
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis. Arch Neurol. 2008;65(6):727–732. doi:10.1001/archneur.65.6.727.
   PubMedGoogle Scholar
• Beck RW, Trobe JD, Moke PS, et al. High and Low-risk profiles for the development of Multiple Sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. 2003;1(7):944–949.
   Google Scholar
• Beck RW, Cleary PA. Optic neuritis treatment trial: one-year follow-up results. Arch Ophthalmol. 1993;111:773–775.
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. New Engl J Med. 1993;329(24):1764–1769. doi:10.1056/NEJM199312093292403.
   PubMed Web of Science ®Google Scholar
• Beck RW. The optic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol. 1995;113:136–137.
   PubMedGoogle Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology. 1999;52(7):1479. doi:10.1212/wnl.52.7.1479.
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology. 1994;44(1):1-4. doi:10.1212/wnl.44.9.1715.
   PubMed Web of Science ®Google Scholar
• Brusaferri F, Candelise L. Steriods for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435–442.
   PubMed Web of Science ®Google Scholar
• Kapoor R, Miller DH, Jones SJ, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology. 1998;50(1):230–237. doi:10.1212/WNL.50.1.230.
   PubMed Web of Science ®Google Scholar
• Naumovska M, Sheikh R, Bengtsson B, Malmsjo M, Hammar B. Visual outcomes is similar in optic neuritis patients treated with oral and i.v. high-dose methylprednisolone: a retrospective study on 56 patients. BMC Neurol. 2018;18(1):160. doi:10.1186/s12883-018-1165-6.
   PubMedGoogle Scholar
• Morrow SA, Fraser JA, Day C, et al. Effect of treating acute optic neuritis with bioequivalent oral vs IV Corticosteroids: a randomized clinical trial. JAMA Neurolol. 2018;75(6):690–696. doi:10.1001/jamaneurol.2018.0024.
   PubMed Web of Science ®Google Scholar
• Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;14:8.
   Google Scholar
• Pineles SL, Balcer LJ. Visual loss: optic neuropathies. In: Liu GT, Volpe NJ, Galetta SL, eds. Neuro-Ophthalmology, Diagnosis and Management. Edinburgh, UK: Elsevier; 2018:101–198.
   Google Scholar
• Stunkel L, Kung NH, Wilson B, McClelland CM, Van Stavern GP. Incidence and Causes of overdiagnosis of optic neuritis. JAMA Ophthalmol. 2018;136(1):76–81. doi:10.1001/jamaophthalmol.2017.5470.
   PubMed Web of Science ®Google Scholar